Comprehensive genomic testing is beneficial for patients at all stages of lung adenocarcinoma, according to a recent study.
NSCLC Patients with Brain Metastases: Look to Molecular Data for Prognostication
Outcomes correlate with the number of brain metastases primarily in patients without two actionable molecular targets: epidermal growth factor receptor mutations or anaplastic lymphoma kinase translocations.